Aravax

MEET US AT We look forward to seeing you in San Diego February 28 – March 3 where we are attending the American Academy of Allergy, Asthma and Immunology - AAAAI annual congress being held in association with Wao. Our senior team members, CEO Pascal Hickey, CSO Sara Prickett, CBO Aled Williams and Director Clinical Operations Annette Leahy will be attending to hear about topics related to climate change and allergic diseases and the global impact on health. They will be meeting with KOLs and clinical investigators, to discuss advantages of our proprietary peptide-based platform technology, designed to precisely retrain the immune system to tolerate allergens, without provoking allergic reactions during treatment and progress with our lead immunotherapy candidate for peanut allergy, PVX108. Well progressed in a multi-site International Phase 2 study in children and adolescents, we are scaling our manufacturing of PVX108 in preparation for Phase 3 development. We believe our groundbreaking technology has the potential to dramatically improve therapeutic options for patients living with food allergies – get in touch to find out more. More about the conference here - https://lnkd.in/gaNesnn #AAAI #FoodAllergies #PeanutAllergy #OIT #immunotherapies #innovation #drugdevelopment #climatechange

POSTER Our CSO Sara Prickett will today be presenting a poster at the Hanson Wade Group 8th Antigen-Specific Immune Tolerance Summit in Boston.   Poster Title: 'Therapeutically relevant immunological changes following PVX108 peptide-immunotherapy for peanut allergy' Poster session timing: 2.10 PM – 2.40 PM Wednesday February 26   The poster presents data from our Phase I trial of PVX108 in adults with peanut allergy that has informed the design of the ongoing Phase 2 trial to assess safety and efficacy in children and adolescents. The data show therapeutically relevant immune changes in samples collected during the Phase I trial and at an 18-month follow-up time point.   Further details on these data and Phase 2 design can be found via our website, or contact us to find more as we continue our preparation for Phase 3 clinical development.   More about the conference here - https://lnkd.in/ezQ82Ze   #AITS #FoodAllergies #PeanutAllergy #OIT #immunotherapies #innovation #drugdevelopment

MEET US AT - We are delighted to be an Industry Partner at the Hanson Wade Group 8th Antigen-Specific Immune Tolerance Summit being held this week 25-27 February in Boston. Our senior team members, CEO Pascal Hickey, CSO Sara Prickett and CBO Aled Williams will be attending, with Sara presenting a poster. We look forward to sharing updates on our progress as we continue our development into an international leader in food allergies, pioneering next-generation targeted immunotherapies that are safe and convenient. Our proprietary platform technology is designed to precisely retrain the immune system to tolerate allergens, without provoking allergic reactions during treatment. Our lead candidate being developed for peanut allergy, PVX108, is well progressed in a multi-site International Phase 2 study, and we are scaling our manufacturing in preparation for Phase 3 development. We believe our groundbreaking technology has the potential to dramatically improve therapeutic options for patients living with food allergies – get in touch to find out more. More about the conference here - https://lnkd.in/ezQ82Ze #AITS #FoodAllergies #PeanutAllergy #immunotherapies #innovation #drugdevelopment

WATCH Thanks Amy Brown of BiotechTV for visiting us in our new facilities on The Oxford Science Park (TOSP) to hear about how we are pioneering next-generation targeted immunotherapies that are safe and convenient. Hear our CEO Pascal Hickey and CSO Sara Prickett explain that from our new base in Oxford, we are scaling our manufacturing of PVX108, a peptide-based immunotherapy for peanut allergy, in preparation for Phase 3 development. They describe how our approach is designed to precisely retrain the immune system to tolerate allergens, without provoking allergic reactions during treatment. Following successful Phase I studies in adults, PVX108, is now well progressed in a multi-site International Phase 2 study in children and adolescents. We believe our ground breaking technology has the potential to dramatically improve therapeutic options for patients living with food allergies. We are backed by leading venture funds including Brandon Capital, Tenmile, Novartis Venture Fund, Breakthrough Victoria, Uniseed and UniSuper. Watch the video here https://lnkd.in/ggmSPisP Visit our website to find out more www.aravax.com.au #FoodAllergies #PeanutAllergy #immunotherapies #innovation #drugdevelopment

NEWS Today we are announcing the appointment of Aled Williams as our new CBO as we continue our international expansion. Aled is hugely experienced having held board, CEO, CBO, CCO and other senior roles at biotech companies across Europe. He is a Non-Executive Director of Destiny Pharma Limited and was CEO of Enthera Pharmaceuticals, CBO of PolyNeuron Pharmaceuticals AG and CCO of Therachon & VectivBio (Switzerland). His pharma experience includes Shire Pharmaceuticals, where he held a number of roles including VP, Product Strategy Head for Rare Disease GI. Prior to Shire, Aled held senior roles at Bristol Myers Squibb, Novartis and Hoffman-La Roche. Aled joins us following the establishment of our UK subsidiary in at the The Oxford Science Park (TOSP) and as we continue to build our international footprint. He’ll be looking to create partnership opportunities for our portfolio as well as evolving our platform and asset strategy. See the full release here: https://lnkd.in/eKQ5J2sB  #FoodAllergies #PeanutAllergy #OIT #immunotherapies #innovation

FAAM-EUROBAT 2024, Food Allergy and Anaphylaxis Meeting & European Consortium on Application of Flow Cytometry in Allergy, is the premier food allergy-focused meeting in the European Academy of Allergy and Clinical Immunology - EAACI calendar. Being held in Athens November 21-23, Aravax's CEO Dr Pascal Hickey and CSO Dr Sara Prickett are attending to gain insights into the field and connect with colleagues and collaborators. PVX108 is an advanced immunotherapy designed to ‘re-train’ the immune system by administering engineered peptides to precisely target T cells and reverse the course of allergic disease. Unlike most treatments available or under development for peanut allergy, PVX108 does not contain peanut proteins which put patients at significant risk of serious side effects and requires burdensome dosing regimens. The company has recently completed recruitment into its Phase 2 study of PVX108 a novel, precision therapy for treating of peanut allergy in the U.S. and Australia. To find out more or meet up, get in touch [email protected] #FoodAllergies #PeanutAllergy #OIT #immunotherapies #innovation #EAACI

Aravax CEO Dr Pascal Hickey and CSO Dr Sara Prickett are looking forward to attending the 2024 Jefferies London Healthcare Conference 19-21 November during London Life Sciences Week (LLSW). The company has recently completed recruitment into its Phase 2 study of PVX108a novel, precision therapy for the treatment of peanut allergy in the U.S. and Australia and expanded international operations with a new base in Oxford, UK. PVX108 is an advanced immunotherapy designed to ‘re-train’ the immune system by administering engineered peptides to precisely target T cells and reverse the course of allergic disease. Unlike most treatments available, or under development for peanut allergy, PVX108 does not contain peanut proteins which puts patients at significant risk of serious side effects and complex and burdensome dosing regimens. To find our more or meet up get in touch - [email protected] #JefferiesHealthcare #FoodAllergies #PeanutAllergy #OIT #immunotherapies #innovation

Aravax’s team is on its way to London to meet with board members and international colleagues converging in London for London Life Sciences Week (LLSW). Having recently announced the opening of its Aravax UK subsidiary based in Oxford with a focus on developing manufacturing capabilities, the company is delighted to have joined the BioIndustry Association (BIA) and looks forward to attending the BIA reception on 17 November – if you are in London, see you there. CEO Pascal Hickey, CSO Sara Prickett and board members Thomas Ulmer Chris Smith. #UKBiotech #FoodAllergies #FoodAllergyAwareness #PeanutAllergy #OIT #immunotherapies #innovation

NEWS Excited to announce Aravax’s expansion and continued development into an international leader in food allergies, establishing a UK subsidiary based on The Oxford Science Park (TOSP). The UK operations will drive the development of commercial manufacturing processes for the peptide drug substances underpinning Aravax’s advanced immunotherapies, as lead candidate PVX108 approaches Phase 3 development. Aravax anticipates investing around US$10m in manufacturing development over the next two years. The UK base also provides Aravax with a truly international footprint for business development. Aravax’s headquarters in Australia will retain responsibility for the Company’s clinical development and other activities. Paul Laidler, Vice President, Pharmaceutical Development, Aravax (UK), said, “Having operations in Oxford provides the opportunity to benefit from the best in UK and European manufacturing expertise for sterile, peptide-based products, and also from the wider worldwide life sciences ecosystem.” Pascal Hickey, CEO of Aravax, said, “Our ambition is to become a global leader in food allergy therapeutics through the development of safe and convenient immunotherapies which meet the critical need for better treatments. We believe this requires an international mindset and capabilities and the setting up of our Oxford operations is a significant step in our development. The company has made great advances with its ground-breaking technology which has the potential to dramatically improve therapeutic options for patients living with food allergies.” See the full release here https://lnkd.in/eK8Msz5r #UKBiotech #Oxford #FoodAllergies #PeanutAllergy #OIT #immunotherapies #innovation #manufacturing

Aravax CEO Pascal Hickey will be speaking at the AusBiotech Conference 2024 in Melbourne next week on a panel titled: “Behind the headlines: Therapeutics development from academic lab, to spin out and exit.” Pascal will share insights from the Aravax journey, including how a pre-clinical asset developed by Professor O'Hehir Robyn, Professor Jennifer Roland, and Dr Sara Prickett spun out of Monash University and Alfred Health has evolved into a clinical-stage company conducting global clinical trials. Join Pascal, Dr Anne-Laure Puaux, Dr Martine Keenan, Dr Janine Bilsborough and Dr Joanne Boag for an engaging conversation about lessons learned and future directions. #BiotechInnovation #TherapeuticsDevelopment #ausbiotech